Literature DB >> 21216812

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Elena Myasoedova1, Cynthia S Crowson, Hilal Maradit Kremers, Veronique L Roger, Patrick D Fitz-Gibbon, Terry M Therneau, Sherine E Gabriel.   

Abstract

OBJECTIVE: To examine the impact of systemic inflammation and serum lipids on cardiovascular disease (CVD) in rheumatoid arthritis (RA).
METHODS: In a population-based RA incident cohort (1987 American College of Rheumatology criteria first met between 1988 and 2007), details were collected of serum lipid measures, erythrocyte sedimentation rates (ESRs), C-reactive protein (CRP) measures and cardiovascular events, including ischaemic heart disease and heart failure. Cox models were used to examine the association of lipids and inflammation with the risk of CVD and mortality, adjusting for age, sex and year of RA incidence.
RESULTS: The study included 651 patients with RA (mean age 55.8 years, 69% female); 67% were rheumatoid factor positive. ESR was associated with the risk of CVD (HR=1.2 per 10 mm/h increase, 95% CI 1.1 to 1.3). Similar findings, although not statistically significant, were seen with CRP (p=0.07). A significant non-linear association for total cholesterol (TCh) with risk of CVD was found, with 3.3-fold increased risk for TCh <4 mmol/l (95% CI 1.5 to 7.2) and no increased risk of CVD for TCh ≥4 mmol/l (p=0.57). Low low-density lipoprotein cholesterol (LDL <2 mmol/l) was associated with marginally increased risk of CVD (p=0.10); there was no increased risk for LDL ≥2 mmol/l (p=0.76).
CONCLUSION: Inflammatory measures (particularly, ESR) are significantly associated with the risk of CVD in RA. Lipids may have paradoxical associations with the risk of CVD in RA, whereby lower TCh and LDL levels are associated with increased cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216812      PMCID: PMC3058921          DOI: 10.1136/ard.2010.135871

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  50 in total

1.  Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.

Authors:  Nick Bansback; Roberta Ara; Sue Ward; Aslam Anis; Hyon K Choi
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 2.  Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.

Authors:  E K Schimmel; Y Yazici
Journal:  Clin Exp Rheumatol       Date:  2009 May-Jun       Impact factor: 4.473

3.  Contemporary treatment principles for early rheumatoid arthritis: a consensus statement.

Authors:  Patrick D W Kiely; Andrew K Brown; Christopher J Edwards; David T O'Reilly; Andrew J K Ostör; Mark Quinn; Allister Taggart; Peter C Taylor; Richard J Wakefield; Philip G Conaghan
Journal:  Rheumatology (Oxford)       Date:  2009-04-28       Impact factor: 7.580

4.  Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis.

Authors:  Cynthia S Crowson; Mahboob U Rahman; Eric L Matteson
Journal:  J Rheumatol       Date:  2009-06-16       Impact factor: 4.666

5.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  J Antonio Aviña-Zubieta; Hyon K Choi; Mohsen Sadatsafavi; Mahyar Etminan; John M Esdaile; Diane Lacaille
Journal:  Arthritis Rheum       Date:  2008-12-15

6.  Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.

Authors:  Gülmisal Güder; Stefan Frantz; Johann Bauersachs; Bruno Allolio; Christoph Wanner; Michael T Koller; Georg Ertl; Christiane E Angermann; Stefan Störk
Journal:  Circ Heart Fail       Date:  2009-09-24       Impact factor: 8.790

Review 7.  Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.

Authors:  David Preiss; Naveed Sattar
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

Review 8.  Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.

Authors:  George Steiner; Murray B Urowitz
Journal:  Semin Arthritis Rheum       Date:  2008-04-18       Impact factor: 5.532

9.  Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure.

Authors:  Gideon Charach; Jacob George; Arie Roth; Ori Rogowski; Dov Wexler; David Sheps; Itamar Grosskopf; Moshe Weintraub; Gad Keren; Ardon Rubinstein
Journal:  Am J Cardiol       Date:  2010-01-01       Impact factor: 2.778

10.  Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.

Authors:  Jonathan Graf; Rebecca Scherzer; Carl Grunfeld; John Imboden
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more
  180 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  Admission Low-Density Lipoprotein Cholesterol Stratified by Circulating CD14++CD16+ Monocytes and Risk for Recurrent Cardiovascular Events Following ST Elevation Myocardial Infarction: Lipid Paradox Revised.

Authors:  Shaozhuang Dong; Wenjie Ji; Shan Zeng; Jun Miao; Lifang Yan; Xinlin Liu; Junxiang Liu; Xin Zhou; Qing Yang
Journal:  J Cardiovasc Transl Res       Date:  2020-06-18       Impact factor: 4.132

Review 3.  Selection bias in rheumatic disease research.

Authors:  Hyon K Choi; Uyen-Sa Nguyen; Jingbo Niu; Goodarz Danaei; Yuqing Zhang
Journal:  Nat Rev Rheumatol       Date:  2014-04-01       Impact factor: 20.543

Review 4.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 5.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

Review 6.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel
Journal:  Am Heart J       Date:  2013-08-29       Impact factor: 4.749

7.  Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Authors:  Katherine P Liao; Jun Liu; Bing Lu; Daniel H Solomon; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

8.  Modulation of autoimmune arthritis severity in mice by apolipoprotein E (ApoE) and cholesterol.

Authors:  P Alvarez; F Genre; M Iglesias; J J Augustin; E Tamayo; J C Escolà-Gil; B Lavín; F Blanco-Vaca; R Merino; J Merino
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

Review 9.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Fei Liu; Baojie Wang; Chunjuan Wang; Bingbing Zhang; Shougang Guo
Journal:  Neurol Sci       Date:  2020-11-20       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.